TNBC cell lines with a mesenchymal (also known as basal B) phenotype are extremely sensitive to apoptosis induced by TRAIL agonists, whereas cell lines representative of the other subtypes (ER+/luminal, HER2 amplified, and basal A TNBC) of breast cancer are comparatively resistant [30,93,94]. Here, ERBB2 is linked to breast carcinoma.